Stockwinners Market Radar for May 24, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:17 EDT Cathie Wood's ARK Investment bought 271.7K shares of Roku today

20:14 EDT Verrica Pharma gets FDA CRL for VP-102 in molluscum contagiosum treatment - Verrica Pharmaceuticals "announced that the FDA has issued a Complete Response Letter regarding its New Drug Application for VP-102 for the treatment of molluscum contagiosum. The only deficiency listed in the CRL was related to the deficiencies identified at a general reinspection of Sterling Pharmaceuticals Services, LLC, the contract manufacturing organization that manufactures Verrica's bulk solution drug product. Sterling advised Verrica on May 20, 2022 that it received notice that it is on OAI status. Sterling's OAI classification resulted from a week-long reinspection of the CMO conducted by FDA in February 2022. The reinspection was conducted approximately 90 days after Sterling was originally classified by the Agency as VAI on November 17, 2021. Verrica understood that the VAI classification did not indicate that a reinspection was required. The CRL did not identify any other deficiencies. Moreover, none of the issues identified by FDA during the reinspection were specific to the manufacturing of VP-102. Additionally, Verrica was informed by the Division that it had completed its review of Verrica's NDA and product label, there were no open questions on the NDA review, and the VP-102 label was ready to be communicated. However, Verrica has been informed that internal FDA policy is preventing the Agency from communicating the label and approving the NDA when a CMO has an unresolved classification status or is placed on OAI status."

19:35 EDT Hudbay Minerals gets favorable U.S. District Court ruling - Hudbay Minerals "received a favorable decision from the U.S. District Court for the District of Arizona relating to the company's Copper World project in Arizona. The District Court ruled in favour of Hudbay on all issues, including that Copper World and Rosemont are not connected under the National Environmental Policy Act and, therefore, that the Army Corps of Engineers does not have an obligation to include Copper World as part of its NEPA review of Rosemont. The District Court also granted Hudbay's motion to dismiss the Copper World preliminary injunction request filed by the plaintiffs in the two lawsuits challenging the Section 404 Clean Water Act permit for Rosemont on the basis that the lawsuits are moot after the company surrendered its 404 permit back to the ACOE in April 2022. The ACOE has never determined that there are jurisdictional waters of the U.S. on the Copper World site and Hudbay has independently concluded through its own scientific analysis that there are no such waters in the area. Hudbay continues to be on track to complete a Preliminary Economic Assessment of Copper World in the second quarter of 2022. "

19:03 EDT Cadence Design executive chair sells $5.75M in common stock - In a regulatory filing, Cadence Design disclosed that Executive Chair Lip-Bu Tan sold 40K shares of common stock on May 20th in a total transaction size of $5.75M.

18:11 EDT Janssen's treatment of PFPR, SFPR granted FDA orphan designation - According to a post on the FDA's website, Janssen's treatment of primary failure of platelet recovery or secondary failure of platelet recovery in patients who have undergone allogeneic hematopoietic stem cell transplant, received FDA orphan designation. Reference Link

17:32 EDT Haymaker Acquisition III stockholders approve business combination with Biote - Haymaker Acquisition Corp. III announced that its stockholders voted to approve the previously announced business combination with Biote, and the related proposals, at Haymaker's special meeting held on May 24. A Form 8-K disclosing the full voting results has been filed with the SEC. The closing of the Business Combination is anticipated to take place on or about May 26. Following closing of the Business Combination, the common stock and warrants of the combined company, called "biote Corp.," are expected to commence trading on the Nasdaq Stock Exchange under the symbols "BTMD" and "BTMDW," respectively, on May 27.

17:16 EDT Wendy's shareholder Trian to explore potential transaction - In a 13D/A filing, Wendy's shareholder Trian stated: "In the course of their discussions with the Board and management of the Company regarding the foregoing matters, on May 24, 2022, the Filing Persons advised the Board that they intend to explore and evaluate the possibility of the Filing Persons' (or one or more of their affiliates') participating, alone or with third parties, in a potential transaction with respect to the Company to enhance shareholder value. Such a potential transaction could include an acquisition, business combination (such as a merger, consolidation, tender offer or similar transaction) or other transaction that would result in the acquisition of control of the Company by the Filing Persons and/or their affiliates, and could include one or more of the types of transactions described in sub-paragraphs (a) through (j) of Item 4 of Schedule 13D. The Filing Persons (or their affiliates) expect to engage in communications and discussions with the Company, members of the Board and management of the Company, other current or prospective shareholders of the Company, potential co-investors and financing sources (including current or potential investors in funds managed by Trian Management), investment and financing professionals, industry analysts and other knowledgeable industry or market observers and participants, and other interested parties regarding a potential transaction and/or the matters set forth in this Item 4, and may exchange information with such persons pursuant to appropriate confidentiality or similar agreements. The Filing Persons (and/or their affiliates) may submit to the Company proposals relating to a potential transaction and may take such other steps as the Filing Persons may deem appropriate from time to time in connection with such a transaction. There can be no assurance that any such proposals will be submitted by the Filing Persons or that any transaction will result from any such discussions or proposals, and the Filing Persons are under no obligation to propose or consummate any transaction. The Filing Persons have retained, and may in the future retain, financial, legal and/or other advisors or consultants to assist them in evaluating their investment in the Company."

17:05 EDT PTC expands roles for two members of its executive team - PTC announced expanded roles for two members of its executive team, both effective immediately. Long-time PTC executive and current president of PTC's Velocity group Mike DiTullio will take over as president of the company's larger Digital Thread group. In addition, PTC's current Chief Strategy Officer Catherine Kniker will expand her charter in a newly formed role as Chief Strategy and Sustainability Officer. Troy Richardson, who has served as president of PTC's Digital Thread group for the past year, will leave the company after a period of transition. During his long career as a sales leader, DiTullio has built deep relationships with PTC customers around the world leveraging the company's entire product portfolio. Assuming leadership of PTC global sales and marketing in 2015, DiTullio helped the company transition to a subscription business model and adopt a digital-first marketing strategy, both of which were key factors in PTC's ability to drive sustained growth throughout the downturn caused by the pandemic. In 2021, DiTullio was named president of PTC's Velocity group, where he has been responsible for managing the company's Onshape and Arena businesses. Related to these developments, Troy Richardson will leave the company after a transition period.

17:02 EDT Rocket Lab announces Varda will procure fourth Photon spacecraft - Rocket Lab and Varda Space Industries announced that Varda will procure a fourth Photon spacecraft. The deal follows on a previous bulk-order by Varda in August 2021 for three Photon spacecraft from Rocket Lab. The Rocket Lab-designed and built Photon spacecraft will provide power, communications, propulsion, and attitude control for Varda's 120 kg in-space manufacturing satellite which will produce high-value products in zero-gravity and return them to Earth in a re-entry capsule. In addition to providing on-orbit support during the in-space manufacturing phase of Varda's mission, the Photons will place Varda's hypersonic re-entry capsule, carrying the finished products, on a return trajectory to markets on Earth using Photon's 3D-printed Curie engine. The Varda contract joins Rocket Lab's growing space systems backlog, which includes a $143M contract with MDA to lead the design and manufacture 17 spacecraft buses for Globalstar's (GSAT) new Low Earth Orbit satellites. A high-energy variant of Rocket Lab's Photon spacecraft was also selected by NASA to deploy the CAPSTONE satellite, owned and operated by Advanced Space, to lunar orbit in 2022 in support of NASA's Artemis program. Rocket Lab currently operates two existing Photon spacecraft on orbit.

16:55 EDT AdaptHealth institutional holder Skyknight Capital buys $3.62M in common stock - In a regulatory filing, AdaptHealth disclosed that one of its top institutional holders, Skyknight Capital, bought 209.3K shares of common stock on May 20th in a total transaction size of $3.62M. Shares of AdaptHealth are up 1.4% at $17.60.

16:44 EDT Flexsteel Industries names Gilbert Huerta as CFO - Flexsteel Industries "announced that Alejandro Huerta will join Flexsteel and assume the role of Chief Financial Officer, Treasurer & Secretary on June 1, 2022, and Derek P. Schmidt will expand his responsibilities as Chief Operating Officer. Mr. Huerta brings over 18 years of progressive financial leadership and general management experience driving profitable growth across multiple industries including consumer products, hospitality and powersports."

16:36 EDT Toll Brothers sees FY22 deliveries 11,000-11,500 units - Sees FY22 average delivered price per home $890,000-$910,000.

16:35 EDT Toll Brothers sees Q3 deliveries 2,750 units - Sees Q3 average delivered price per home $895,000-$915,000.

16:32 EDT Toll Brothers reports Q2 backlog $11.7B, up 35% - Backlog value was $11.7 billion at second quarter end, up 35% compared to FY 2021's second quarter; homes in backlog were 11,768, up 16%. Net signed contract value was $3.1 billion, up 1% compared to FY 2021's second quarter; contracted homes were 2,874, down 18%. Home sales gross margin was 24.1%, compared to FY 2021's second quarter home sales gross margin of 21.9%. Adjusted home sales gross margin, which excludes interest and inventory write-downs, was 26.1%, compared to FY 2021's second quarter adjusted home sales gross margin of 24.4%. SG&A, as a percentage of home sales revenues, was 11.1%, compared to 11.9% in FY 2021's second quarter.

16:19 EDT Telos announces $50M share repurchase authorization - Telos announced that its Board of Directors authorized a share repurchase program for up to $50M of the Company's common stock. "This share repurchase program underscores the confidence that the Board of Directors and senior management have in the Company's performance and our commitment to creating shareholder value," said John B. Wood, CEO and chairman, Telos. "We will continue to balance our capital allocation strategy between investment in organic growth and inorganic growth, prudent management of our balance sheet and liquidity profile, and now also distribution of capital to shareholders." Under the repurchase program, Telos may purchase shares of its common stock on a discretionary basis from time to time through open market repurchases, privately negotiated transactions, or other means, including through Rule 10b5-1 trading plans. The timing and actual number of shares repurchased will be determined by management depending on a variety of factors, including stock price, trading volume, market conditions, the Company's cash flow and liquidity profile, and other business considerations. The repurchase program has no expiration date and may be modified, suspended, or terminated at any time.

16:16 EDT U.S. Well Services announces contract for newbuild Nyx Clean Fleet - U.S. Well Services announced it has finalized a contract with one of the largest E&P producers in the U.S., to provide electric pressure pumping services. Under the terms of the agreement, USWS will dedicate a newbuild Nyx Clean Fleet to support the Customer's development program in Texas for an initial term of 18 months beginning early in the Q3.

16:14 EDT Nordstrom up 12% after Q1 report, Macy's up 4% in sympathy - Macy's (M) shares are up 71c, or 4%, to $18.33 in after-hours trading following the Q1 report from department store peer Nordstrom.

16:12 EDT Nordstrom jumps 12% to $23.07 after FY22 guidance tops estimates

16:10 EDT RCI Hospitality increases amount of share repurchase program by $25.0M - RCI Hospitality Holdings Board of Directors today authorized increasing the amount available under the company's share repurchase program by an additional $25.0M. From FY16, when the company started implementing its capital allocation strategy, to Q2, RCI has invested approximately $25.4M repurchasing approximately 1.6M shares at an average of $15.88 per share.

16:07 EDT COMSovereign Holding receives not in compliance letter from Nasdaq - COMSovereign Holding announced that it has received a letter from the Listing Qualifications Department of the Nasdaq Stock Market stating that the Company is not in compliance with Nasdaq Listing Rule 5250 because the Company failed to timely file its Annual Report on Form 10-K for the year ended December 31, 2021 and its Quarterly Report on Form 10-Q for the period ended March 31 with the SEC. Under Nasdaq rules, the Company has until June 20 to submit a plan to regain compliance with respect to these delinquent reports. If Nasdaq accepts the Company's plan, it may grant an exception of up to 180 calendar days from the Filing's due date, or until October 12 for it to regain compliance.

16:05 EDT Redbox acquires North American rights to WWII action-drama Come Out Fighting - Redbox Entertainment announced it has acquired North American distribution rights to WWII action-drama Come Out Fighting. The film stars Kellan Lutz as Lieutenant Frank Ross, and Michael Jai White as Sergeant AJ 'Red' McCarron, and is written and directed by Steve Luke. The film will premiere in 2022 and is expected to have a limited theatrical run and be available day-and-date On Demand. "This is a fascinating snapshot during one of the most tumultuous times in modern history," said Galen Smith, CEO of Redbox. "This story is a testament to the enduring human spirit, and to what can be accomplished when people who, on the surface, have nothing in common, yet work together against immeasurable odds."

16:03 EDT Innoviz Technologies appoints Tali Chen as Chief Business Officer - Innoviz Technologies announced a series of management team appointments to bolster its sales leadership experience and support its continued growth. Innoviz has appointed Tali Chen as Chief Business Officer, effective immediately. Chen will oversee the Company's business development activities, establish sales targets and KPIs, and implement, report and review strategic sales and marketing plans. Chen replaces Oren Rosenzweig, who is stepping down from his CBO and Board roles, effective immediately, to pursue new opportunities. Rosenzweig will continue in an active advisory role through summer 2022 to ensure a smooth transition. Chen most recently served as CBO for DSP Group, a global leader in wireless communications for smart-enabled devices. In this role, she managed global sales, marketing, investor relations and business growth operations. The Company also announced that it has appointed Scott Craig and Brijesh Shukla as country managers of the U.S. and Japan, respectively.

14:19 EDT Google debuts new shopping ad formats with Performance Max campaigns - On the Ads & Commerce Blog, Jerry Dischler, Vice President / General Manager, of Google Ads wrote in part: " Technology is powering more business growth around the world than ever before. And new consumer behaviors are redefining the role technology plays in everyday life...Consumers are turning to Google Search and YouTube more than ever for help with purchase decisions. In fact, we see over one billion shopping journeys happen across Google every day, When it comes to shopping on Google Search, we've made the experience more natural and intuitive...However, nothing can quite replace seeing a product in person or bringing it home to try out. Augmented reality, AR, on cameras gets us close, and shoppers are ready for it. More than 90% of Americans currently use, or would consider using, AR for shopping. Soon, merchants will be able to have 3D models of their products appear directly on Google Search, allowing shoppers to easily see them in their spaces...Using Performance Max campaigns - along with a product feed - you'll be able to drive more online loyalty sign-ups across YouTube, Display, Search, Discover, Gmail and Maps. Starting today, your Video action campaigns and App campaigns will automatically scale to YouTube Shorts...Performance Max campaigns are a powerful tool for helping you meet consumers where they are across Google channels. In fact, advertisers that use Performance Max campaigns in their account see an average increase of 13% total incremental conversions at a similar cost per action. We're announcing six upcoming additions," said Google, including more tools for experimentation, like A/B tests to see how Performance Max is driving incremental conversions expanded campaign management support in Search Ads 360 and the Google Ads mobile app and support for store sales goals... "At Google we're driven by a shared goal: to be the most helpful company in the world," noted the company in a statement. Reference Link

13:43 EDT Microsoft updates Windows 11 Store for developers utilizing 'open platform' - On the Windows Blogs page, Panos Panay, Chief Product Officer, Windows and Devices wrote, in part: " As a team, we're thrilled to spend time with the developer community at Microsoft Build... we are sharing new updates to Windows 11 and the Microsoft Store for developers including: New app building tools to enable you to take your existing code and make it incredibly compelling on Windows...We are building toward our vision for a world of intelligent hybrid compute, bringing together local compute on the CPU, GPU, and NPU and cloud compute with Azure... In the future, moving compute workloads between client and cloud will be as dynamic and seamless as moving between Wi-Fi and cellular on your phone. Bringing Azure and Windows closer together will enable you to bring new classes of applications to life for your commercial and consumer customers. This journey begins with Windows 365, Xbox Cloud Gaming, and Azure Virtual Desktop and will continue with cloud and NPU processing on more Windows devices. We will also continue to bridge toward this future, utilizing our open platform, open store, and open hardware ecosystem to empower you to bring your skills, talent, and passion forward. Our goal with the open platform of Windows is to make it easy for you to build and run your apps on Windows, whether they're .NET, web, Android, C++, Linux, or any number of cross-platform frameworks. This makes it easy to use Windows for all your developer workflows and distribution models and reach more users to build your business your way." Reference Link

13:39 EDT Grupo Simec trading resumes

13:24 EDT Glencore reports coordinated resolutions with U.S., UK and Brazilian authorities - Glencore announced that it has resolved the previously disclosed investigations by authorities in the United States, the United Kingdom and Brazil into past activities in certain Group businesses related to bribery, and separate U.S. investigations related to market manipulation. Glencore cooperated with these investigations. "Under the terms of the US resolutions, Glencore will pay penalties of $700,706,965 to resolve bribery investigations and $485,638,885 to resolve market manipulation investigations by the Department of Justice and the Commodity Futures Trading Commission. Of this amount, up to $165,930,959 will be credited against other, parallel matters, including in the UK, so that the net amount payable to the US authorities is expected to be $1,020,414,891. Glencore has further agreed to pay $39,598,367 under a resolution signed with the Brazilian Federal Prosecutor's Office in connection with its bribery investigation into the Group. Glencore Energy UK Limited has also today indicated that it will plead guilty to charges brought by the UK Serious Fraud Office in respect of its bribery investigation. The penalty to be paid will be determined following a sentencing hearing currently scheduled for 21 June 2022. Glencore does not currently anticipate that the amount to be paid in respect of the UK resolution will result in the aggregate amount being paid for all of the above resolutions differing materially from the $1,500 million provision recorded in the Company's 2021 financial statements. The plea agreements entered into by Glencore International AG and Glencore Ltd. with the DOJ each provide for the appointment of an independent compliance monitor for a period of three years to assess and monitor the Company's compliance with the agreements and evaluate the effectiveness of its compliance programme and internal controls. Glencore continues to cooperate with a previously disclosed and ongoing investigation by the Office of the Attorney General of Switzerland into Glencore International AG for failure to have the organisational measures in place to prevent alleged corruption, and an investigation of similar scope by the Dutch Public Prosecution Service. The timing and outcome of these investigations remain uncertain," the company stated in a notice to the London Stock Exchange.

12:59 EDT BML reports stake in Forte Biosciences, asks for liquidation - BML Investment Partners reported an 8.94% stake in Forte Biosciences, which represents 1.32M shares. The filing with the SEC allows for activism. On May 24, 2022, BML's Braden Leonard sent an email to Forte Biosciences Chairman and CEO Paul Wagner indicating that BML believes that the company should liquidate and return cash to shareholders. The email reads in part, "After spending some time reflecting on the outcome of the strategic review, it has become clear to me that shareholders would be far better off if the Board had decided to liquidate the company and return cash to shareholders rather than pushing forward with its current plan. FB-102 was not even mentioned until the 10-K filed on 3/31/22, giving the strong impression that the company's new "lead drug" was nothing more than an afterthought until recently...It seems to me that the Board didn't seriously consider liquidation and that the company is being run for the benefit of the few remaining employees rather than shareholders. Had the Board taken decisive action to liquidate, the company could have returned $2.50 to $2.60 per share to shareholders, which is approximately 130-140% above the current quote. This is likely a far better outcome for shareholders than what's to come under the current plan...We strongly recommend that the Board take decisive action to immediately liquidate the company and return cash to shareholders before additional shareholder capital is wasted."

12:18 EDT FanDuel appoints Andrew Sheh chief technology officer - FanDuel Group announced that it has appointed Andrew Sheh as Chief Technology Officer. Sheh will be responsible for oversight of FanDuel Group's customer facing engineering and platform development teams, as well as all IT architecture and personnel. Sheh joins FanDuel Group most recently from Compass. FanDuel Group is a subsidiary of Flutter Entertainment.

12:00 EDT Abercrombie & Fitch falls -30.4% - Abercrombie & Fitch is down -30.4%, or -$8.12 to $18.61.

12:00 EDT Snap falls -40.3% - Snap is down -40.3%, or -$9.06 to $13.41.

12:00 EDT Daily S&P Biotech Bear 3x Shares rises 9.0% - Daily S&P Biotech Bear 3x Shares is up 9.0%, or $4.94 to $59.78.

11:57 EDT Global Blood Therapeutics' Inclacumab granted FDA orphan designation - Global Blood Therapeutics' Inclacumab was granted FDA orphan designation as a treatment of Sickle Cell Disease, according to a post to the agency's website. Reference Link

11:52 EDT CSX head of sales says 'nothing really changed' in terms of FY guidance - At the Wolfe Research Global Transportation and Industrials conference, analyst Scott Group asked: "So guidance implies we see year-over-year inflection positive volumes in second half of the year. You've guided to double-digit revenue growth for the year, double-digit operating income growth. Anything changing in terms of any of those?" to which CSX Head of Sales Kevin Boone replied: "No, I think overall, nothing has changed. You'll have moving parts, obviously, but nothing has really changed from that guidance."

11:30 EDT Peloton CEO: 'You'd have to be a moron to sell equity' at this stock level - CEO Barry McCarthy said that at the current price, "you'd have to be a moron to sell equity" unless there's some "spectacular" increase in value that would happen as a result of a strategic alignment that is going to significantly accelerate the growth and value of the business. McCarthy thinks it's "unlikely" that a strategic partner could so significantly shift the business.

11:16 EDT Connecticut AG announces $19.2M multistate settlement with Ford - Connecticut Attorney General William Tong has announced a $19.2 million multistate settlement with Ford Motor regarding claims that Ford falsely advertised the real-world fuel economy of model year 2013-2014 C-Max hybrids and the payload capacity of model year 2011-2014 Super Duty pickup trucks. Connecticut will receive $253,229.65 from the settlement. Ford has separately paid $35 million in direct restitution to C-MAX lessees and owners. According to a statement, "the investigation revealed that Ford made several misleading representations about 2013-2014 C-Max hybrids including: Misrepresenting the distance consumers could drive on one tank of gas; Marketing that driving style would not impact real world fuel economy; and Claiming superior real world fuel economy compared to other hybrids." The settlement was led by Oregon, Texas, Illinois, Maryland, Vermont and Arizona, and joined by the Attorneys General of 35 additional states and jurisdictions.Reference Link

11:13 EDT Procore, Shepherd partner on insurance product - Procore Technologies announced a new partnership with Shepherd to begin offering an integrated insurance product that provides improved insurance terms and lower premiums to qualified Procore customers.

11:10 EDT Peloton CEO: 'I don't care' about Connected Fitness, gross margins - CEO Barry McCarthy, when asked if the company can return to 50% gross margins, said "I don't care about Connected Fitness or gross margins." McCarthy said he cares about "lifetime value, how much we spend in marketing to acquire a sub and how much that sub is going to generate for us in profit over their lifetime." Comments taken from JPMorgan's Global Technology, Media and Communications Conference.

11:09 EDT Sun Life Financial renews partnerhsip with Kansas City Royals - Sun Life U.S. has renewed sponsorship of the Kansas City Royals, a partnership first established in 2016. This partnership renewal will enhance Sun Life's hosting opportunities by including away games, and will deepen investments in local community initiatives through the #StrikeoutDiabetes and "Fun at Bat" programs. Sun Life has worked with Royals Charities to support various local organizations that offer diabetes programs and promote health and fitness.

11:07 EDT Conifer Health enters multiyear agreement with Brookwood Baptist Health - Conifer Health Solutions and Brookwood Baptist Health announced the launch of a new multi-year, multi-facility service agreement. Under the terms of the agreement and building on its existing relationship with Brookwood Baptist Hospital, Conifer is now providing comprehensive revenue cycle services to four additional hospitals within Brookwood Baptist Health. Those services include patient access, eligibility enrollment services, and accounts receivable management.

10:49 EDT Walmart expands drone delivery to six states through DroneUp partnership - In a blog post, David Guggina, SVP of innovation and automation, Walmart U.S. said, "We continue to expand our delivery operations to help customers get the items they need when they need them, and it's been an exciting journey. From Express delivery, where customers can have items delivered to their doorsteps in as little as two hours, to InHome, where they can get those orders placed right into their refrigerators, we're proud to offer customers multiple options that help them save time and money. One solution we've been working on over the last year is delivery via drone. Today we're announcing we'll be expanding our DroneUp delivery network to 34 sites by the end the year, providing the potential to reach 4 million U.S. households across six states - Arizona, Arkansas, Florida, Texas, Utah and Virginia. This provides us the ability to deliver over 1 million packages by drone in a year. Between the hours of 8:00 a.m. and 8:00 p.m., customers will be able to order from tens of thousands of eligible items, such as Tylenol, diapers and hot dog buns, for delivery by air in as little as 30 minutes. For a delivery fee of $3.99, customers can order items totaling up to 10 pounds, so simply put, if it fits safely it flies...Participating stores will house a DroneUp delivery hub inclusive of a team of certified pilots, operating within FAA guidelines, that safely manage flight operations for deliveries. Once a customer places an order, the item is fulfilled from the store, packaged, loaded into the drone and delivered right to their yard using a cable that gently lowers the package." Reference Link

10:01 EDT Cytek Biosciences receives CE Marking for series of cFluor reagents, TBNK kit - Cytek Biosciences announced that a series of single-color cFluor reagents and a 6-color TBNK kit have received CE Marking under the European Union In Vitro Diagnostic Medical Devices Directive 98/79/EC. Other regions that accept the CE marking are also included in the certification. This achievement makes cFluor reagents available for clinical diagnostic use in hospitals, laboratories and clinics across Europe, and positions the company on a path to offering a total cell analysis solution to the European market - from instruments to reagents.

10:00 EDT BigBear.ai falls -28.4% - BigBear.ai is down -28.4%, or -$2.87 to $7.25.

10:00 EDT Small Cap Bear 3x rises 5.2% - Small Cap Bear 3x is up 5.2%, or $2.23 to $45.34.

10:00 EDT Daily S&P Biotech Bear 3x Shares rises 9.2% - Daily S&P Biotech Bear 3x Shares is up 9.2%, or $5.06 to $59.90.

09:54 EDT Verizon CFO: Competition, inflation 'temper' expectations for consumer volumes - Competition, inflation "temper" the company's expectations for consumer volumes in Q2, CFO Matt Ellis said at the JPMorgan Global Technology, Media and Communications Conference 2022.

09:50 EDT Polaris Infrastructure to change name to Polaris Renewable Energy - Polaris Infrastructure announced that it will be holding its Annual General Meeting virtually for all Shareholders on June 23, 2022 via Lumi. The Management Information Circular for the AGM has been mailed today to all Shareholders as of the record date of May 9, 2022 . Furthermore, the Company is also pleased to announce that, subject to receipt of Shareholder approval at the AGM, the Company is planning to change its name to Polaris Renewable Energy Inc. This is in response to recent and projected future growth resulting in a renewal of its corporate vision. Announcements revolving around such re-branding will be forthcoming after the AGM if shareholder approval has been received.

09:47 EDT BigBear.ai falls -27.0% - BigBear.ai is down -27.0%, or -$2.73 to $7.39.

09:47 EDT KBR rises 5.2% - KBR is up 5.2%, or $2.47 to $49.85.

09:47 EDT Youdao rises 5.8% - Youdao is up 5.8%, or 32c to $5.84.

09:39 EDT WalkMe Ltd trading resumes

09:35 EDT SAI.TECH Global Corp trading resumes

09:31 EDT Ralph Lauren expects all 3 regions to drive positive revenue growth this year

09:30 EDT SAI.TECH Global Corp trading halted, volatility trading pause

09:25 EDT Ralph Lauren sees growth in owned and wholesale digital in FY23

09:23 EDT Ralph Lauren: Foreign tourism remains 'muted'

09:20 EDT Camber Energy regains compliance with NYSE - Camber Energy announced that it received a letter from the NYSE advising the company is back in compliance with the exchange's continued listing standards set forth in Part 10 of the NYSE American Company Guide given the company filed with the Securities and Exchange Commission previously outstanding financial reports.

09:17 EDT Ralph Lauren: Revenues now slightly ahead of pre-pandemic level

09:12 EDT Recruiter.com annnounces update to AI recruiting software platform - Recruiter.com Group announced updates to its artificial intelligence recruiting software platform. Xuan Smith, Recruiter.com's CTO, recently demonstrated the updated components of Recruiter.com AI, which speeds up the sourcing and hiring process, and debuted a new candidate tracking platform for employers. Updates to the recruiting software platform highlighted by Smith include: Improved search capability - Search for qualified candidates for job openings by current or previously held job titles, industry, geographic location, hard skills, and more. Improved email outreach - Send outreach emails to the most qualified candidates faster. Also, create outreach sequences and A/B test different subject lines to improve engagement with passive candidates. A new candidate tracker dashboard that allows employers to review each candidate's background in one integrated view and quickly approve or deny candidates, further clarifying the candidate search process. Recruiter.com's new candidate tracker allows companies to manage a candidate pipeline efficiently. The candidate tracker curates a list of potential candidates, reviews candidates' backgrounds and skills in relation to the job, and allows employers to streamline their pipeline by adding notes when deciding which job candidates to select for the interview process. When paired with the Recruiter.com Recruiters On Demand service, the solution delivers not only qualified and engaged candidates but screened and "ready-to-interview" talent. This enables the employer or in-house talent acquisition team to focus on speaking with ideal candidates rather than on sourcing and screening hundreds of people.

09:11 EDT PagerDuty expands international presence to Japan - PagerDuty announced the expansion of its Japanese operations through a strategic partnership with Japan Cloud. PagerDuty's digital operations platform has become critical infrastructure as companies across industries accelerate their plans for digital transformation. The new joint venture, PagerDuty Japan, further enables PagerDuty to support this transition with an experienced local team. As PagerDuty scales towards $1b of revenue, Japan offers significant expansion opportunities for PagerDuty led by cloud adoption, digital acceleration and DevOps transformation. Enterprise operations are continuous and complex, but the operating systems most companies rely on haven't evolved. With PagerDuty, organizations of all sizes can proactively manage their digital operations from anywhere, preventing disruptions and allowing them to spend less time reacting and more time building the future.

09:09 EDT Fortinet introduces FortiNDR network detection, response offering - Fortinet announced FortiNDR, a new network detection and response offering that leverages powerful artificial intelligence and pragmatic analytics to enable faster incident detection and an accelerated threat response. Security operations teams are faced with advanced, persistent cybercrime that is more destructive and less predictable than ever before, an attack surface that continues to expand with hybrid IT architectures, and ongoing staff shortages due to the cybersecurity skills gap. Those using legacy security solutions are also challenged with overwhelming and tedious manual alert triage that pulls important resources away from high-priority tasks such as mitigating threats. As cybercriminals become more sophisticated, so too must an organization's security tools.

09:08 EDT WooCommerce and Affirm expand partnership with Canada launch - WooCommerce, "the flexible, open-source commerce solution built on WordPress, and Affirm the payment network that empowers consumers and helps merchants drive growth, today announced a deepened partnership to provide WooCommerce merchants the opportunity to offer consumers the ability to pay over time through Affirm," said the company in a statement' WooCommerce has 3.7M merchants, including brands such as Gardyn, Tonal, Mint Mobile & Teeter..."Our expanded global partnership with WooCommerce will unlock greater opportunities for our businesses as we empower more merchants with our solutions, including our thousands of shared partners," said Scott Williams, Vice President of Strategic Partnerships at Affirm.

09:07 EDT Agora announces top management appointments - Agora announced the promotion of key executives and a new hire designed to drive innovation and reinforce security as Agora continues its growth globally. Effective immediately, Stanley Wei will expand his responsibilities as Chief Strategy Officer to lead strategy as well as commercial operations globally. Agora Co-founder Tony Wang is named the Chief Revenue Officer, while Agora veteran Virginia Liu becomes Agora's first-ever Chief Experience Officer, both effective immediately. Agora is also announcing the hiring of Roger Hale, the former Chief Security Officer at BigID, a data-centric personal data privacy and protection company. He joins Agora as Chief Security Officer. Wei is responsible for overall strategic planning, investments and global expansion. He is also tasked with overseeing the day-to-day administrative and operational functions of the business. He reports to Zhao. As CRO, Wang, an Agora co-founder and leader of the Agora's Emerging Technology & Markets division, will now lead sales strategy, management and team development. He will also own the go-to-market strategy, identify and close key accounts, while ensuring customer retention. He reports to CSO Wei. In the CXO role, Liu, who transitions from her position as Agora's Senior Vice President of Marketing & Ecosystems, will drive Agora's product-led growth (PLG) strategy, aligning Agora's product strategy to make it extremely easy and delightful for developers to build high-quality real-time applications. She will report to CEO Zhao.

09:05 EDT GeoVax Labs receives notice of allowance for cancer vaccine patent in China - GeoVax Labs announced that the Chinese Patent Office has issued a Notice of Allowance for GeoVax's patent application titled "Compositions and Methods for Generating an Immune Response to a Tumor Associated Antigen." The claims to be granted by the patent generally cover GeoVax's vector platform for expressing tumor associated antigens in virus-like particles from a Modified Vaccinia Ankara viral vector and encompass GeoVax's Mucin 1 tumor-associated antigen immunotherapy candidate. The Company uses its GV-MVA-VLP vaccine platform to express abnormal, aberrantly glycosylated forms of the cell surface-associated MUC1 protein that is associated with a wide range of cancers, including breast, colon, ovarian, prostate, pancreatic, and lung. David Dodd, GeoVax President and CEO, commented, "This patent allowance complements the previously issued U.S. Patent No. 11278607, demonstrating the global importance of this technology, and adding to our growing portfolio of wholly owned, co-owned, and in-licensed intellectual property, which now stands at over 70 granted or pending patent applications spread over 20 patent families. GeoVax is committed to advancing meaningful cancer immunotherapies towards improving the lives of patients worldwide."

09:05 EDT Bank of America and Electrify America plan to double EV charging stations - Bank of America and Electrify America announced plans to more than double the number of financial centers equipped with electric-vehicle, or EV, charging stations by the end of 2023. As of the beginning of this year, 172 Electrify America individual EV chargers have been installed at 46 financial centers - totals the companies intend to grow to more than 350 chargers at over 90 financial centers by the end of 2023.

09:03 EDT Lincoln Educational announces $30M share repurchase program - Lincoln Educational Services announced that its Board of Directors has authorized a share repurchase program of up to $30M of the Company's outstanding common stock. The repurchase program has been authorized for twelve months. "Our Board of Directors' decision to authorize this share repurchase program reflects our continued confidence in our strategy to grow Lincoln while maximizing shareholder returns," said Scott Shaw, President and Chief Executive Officer. "Our financial performance, near and long-term outlook, and returns from recent real estate transactions have combined to enable the creation of this opportunity to build shareholder value without compromising our ability to invest in key higher-growth opportunities to achieve further success, such as new programs and campuses."

09:03 EDT Ralph Lauren: Consumer remains 'healthy, motivated' - Comments taken from Q4 earnings conference call.

09:02 EDT Arthur J. Gallagher acquires Frederickson Partners for undisclosed amount - Arthur J. Gallagher & Co. announced the acquisition of Menlo Park, California-based Valerie Frederickson & Company, dba Frederickson Partners. Terms of the transaction were not disclosed. Founded in 1995, Frederickson Partners is a human resources retained executive search and advisory firm, and a leader in diversity, equity and inclusion. The team recruits Chief Human Resources Officers, Chief People Officers, Chief Diversity Officers and other critical HR executives for leading technology, fintech, biotech, insurance, gaming and retail organizations. Frederickson Partners has locations in a dozen cities across the U.S., including San Francisco, New York, Dallas, Chicago, Los Angeles and Nashville, and also serves global tech hubs London, Berlin, Paris, Mexico City, Bogota, Seoul and Sao Paulo. Founder Valerie Frederickson and her team will continue to operate under the direction of Scott Hamilton, Global Managing Director, Human Resources & Compensation Consulting, for Gallagher's employee benefits consulting and brokerage operations.

08:51 EDT Jaguar Health presents investigator-initiated evaluation of crofelemer - Jaguar Health announced the presentation of an investigator-initiated in vitro study evaluating the efficacy of crofelemer, the company's plant-based prescription drug, as a potential anti-diarrheal to mitigate the consequences of microvillus inclusion disease, a severe congenital diarrheal disorder, at Digestive Disease Week, which took place May 21-24, 2022 in San Diego, CA. "Microvillus inclusion disease is a life-threatening and rare autosomal recessive disease that affects newborns and children resulting in significant morbidity and mortality from severe secretory diarrhea," said Pravin Chaturvedi, PhD, Jaguar Health's Chief Scientific Officer and Chair of the company's Scientific Advisory Board. "We expect the results of this study to be supportive of Napo Therapeutics' Orphan Drug Designation application to the European Medicines Agency for crofelemer for this congenital diarrheal disorder. Napo Therapeutics is the Italian corporation established by Jaguar Health in Milan, Italy in 2021 that focuses on expanding crofelemer access in Europe." This study characterized for the first time the cellular phenotype of MVID using primary patient-derived duodenal enteroids. The results of this study demonstrate that crofelemer has the clinical potential for symptomatic therapy and electrolyte and fluid management in MVID patients. Click here to view the study abstract. This study was conducted and presented by Jay Thiagarajah, MD, PhD, who is Co-Director of the Congenital Enteropathy Program, and an Attending Physician in the Division of Gastroenterology, Hepatology and Nutrition, at Boston Children's Hospital, Harvard Medical School, where Dr. Thiagarajah also serves as Assistant Professor of Pediatrics.

08:47 EDT Senti Bio announces effectiveness of registration statement on Form S-4 - DYNS and Senti Bio also announced that the registration statement on Form S-4 filed in connection with DYNS's and Senti Bio's previously announced proposed business combination was recently declared effective by the U.S. Securities and Exchange Commission. The Registration Statement provides important information about DYNS, Senti Bio and the proposed business combination. The meeting of stockholders of DYNS will be held on June 7, 2022 at 10:00 a.m. ET via live webcast at the following address: https://www.cstproxy.com/dspc/2022. At the meeting, DYNS's stockholders will be asked to vote on proposals to approve the proposed business combination and related matters. DYNS's stockholders of record as of May 3, 2022 are eligible to attend and vote at the meeting.

08:41 EDT Moderna says investigating potential monkeypox vaccines at 'preclinical level' - In a series of tweets yesterday, Moderna stated: "In March of 2022, we announced our commitment to advancing programs by 2025 against #pathogens that pose a threat to public health. Underscoring this commitment, and as #monkeypox is of global public health importance as identified by the @WHO, we are investigating potential monkeypox vaccines at a preclinical level." Reference Link

08:41 EDT Volcon expands revenue stream, signs distribution agreement with Torrot - Earlier this month, Volcon signed an exclusive distribution agreement with Torrot Electric Europa to distribute Torrot's line of electric off-road motorcycle products throughout Latin America, South America, and the Caribbean Region, LATAM. This agreement is expected to provide Volcon with an immediate opportunity to improve revenue and profitability by selling quality, "off-the-shelf" products throughout Volcon's existing and expanding LATAM dealer and distributor network. "Working with Torrot has been a great experience thus far. We've quickly identified several opportunities, with the most obvious being the ability to distribute the Torrot lines of products in our existing Latin American, South America, and Caribbean markets," explained Jordan Davis, CEO of Volcon ePowersports. "This agreement will create opportunities to quickly realize additional revenue with little to no additional overhead as we are able to utilize our existing resources and the expert sales and logistics teams that are already in place at Volcon."

08:39 EDT Quantum Computing announces agreement to acquire QPhoton - Quantum Computing announced that it has entered into a definitive agreement to acquire QPhoton, a quantum photonics innovation company that has developed a series of quantum photonic systems, QPS. "The acquisition of QPhoton extends QCI's offerings to accelerate the accessibility of quantum computing, and other powerful technologies, into easily deployable solutions today, and advances QCI into a full-spectrum quantum software and hardware company," the company said. "This acquisition is key to QCI delivering on its commitment to be the democratizing force that empowers non-quantum experts to realize quantum value," stated Robert Liscouski, CEO of QCI. "The combination of QPhoton's powerful quantum processing technology and systems with QCI's Qatalyst software significantly accelerates accessibility to quantum solutions for real business problems. Just a year ago this quantum functionality seemed far off. QCI, with QPhoton's technology, will be launching ready-to-run anywhere, full-stack quantum systems that can deliver affordable, user-friendly solutions for real business problems to a much larger audience." QPhoton will be a wholly-owned subsidiary of QCI, and Dr. Yuping Huang, CEO of QPhoton is expected to join QCI as a director and officer. Under the definitive agreement, at the closing of the proposed transaction, QCI will issue to QPhoton's stockholders aggregate merger consideration consisting of: 5,802,206 shares of QCI's common stock, 2,377,028 shares of a new series of QCI's preferred stock, convertible into 23,770,280 shares of common stock, and warrants exercisable, at a purchase price of $0.0001 per share, to purchase up to 7,028,337 shares of common stock. The transaction is expected to close during the third or fourth quarter of 2022 and is subject to customary and other closing conditions.

08:38 EDT Synchrony and Sweetwater extend strategic partnership - Synchrony and Sweetwater announced an extension of their strategic partnership to further transform Sweetwater's financing program. The Synchrony and Sweetwater partnership will focus on driving growth through enterprise data sharing and the digital transformation of payment solutions. Sweetwater will continue to incorporate Data Share and Synchrony's Direct to Device and PreQualification capabilities as part of the company's private label credit card program, simplifying the application and purchase process.

08:36 EDT ClearSign Combustion receives government grant through SBIR program - ClearSign Technologies announces that the Company was awarded a government grant through the Small Business Innovative Research, or SBIR, program with the Department of Energy. The goal of this project is to develop ultra-low NOx hydrogen burner technology which will enable the adoption of hydrogen fuel for industrial heating, leading to reductions in the industrial emissions of both carbon dioxide and nitrogen oxides. Current burners and previous efforts to decarbonize industrial combustion processes through the utilization of hydrogen fuel are inhibited by the lack of industrial hydrogen burners capable of burning pure hydrogen while preventing additional Nitrogen Oxides, or NOx, emissions. The project and funding are in phases. The initial funding amount is approximately $250,000 and the project will last six months starting at the end of June. If needed, and upon completion of the Phase 1 work, the Company will be able to submit a follow-up proposal to continue the development work with a Phase 2 grant. Phase 2 grant funding can be up to $1.6M for a two-year duration.

08:34 EDT P3 Health announces receipt of Nasdaq notice regarding periodic reports - P3 Health Partners announced that on May 18, 2022, it received a notice from the Listing Qualifications Department of the Nasdaq Stock Market indicating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of not having timely filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2021 or its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2022 with the Securities and Exchange Commission. As previously disclosed in the Company's Current Report on Form 8-K filed with the SEC on April 25, 2022 and its form 12b-25 filed with the SEC on May 16, 2022, the Company is currently completing a restatement related to the Company's consolidated financial statements for the years ended December 31, 2020 and 2019 and unaudited condensed consolidated financial statements for the interim quarterly periods ended September 30, 2021, June 30, 2021, March 31, 2021, September 30, 2020, June 30, 2020 and March 31, 2020. The Nasdaq notice has no immediate effect on the listing or trading of the Company's common stock on the Nasdaq Capital Market. The Notice provides that the Company has 60 calendar days from the date of the Notice, or July 18, 2022, to submit a plan to regain compliance with Nasdaq Listing Rule 5250(c)(1).

08:33 EDT Journey Medical announces settlement agreements pertaining to patent exclusivity - Journey Medical announced that Journey Medical and Padagis US entered into a settlement agreement pertaining to the patents protecting QBREXZA, the first and only prescription cloth towelette for the treatment of primary axillary hyperhidrosis, AMZEEQ, the first and only topical minocycline product for the treatment of acne, and ZILXI, the first and only topical minocycline product for the treatment of rosacea. Under terms of the paragraph IV settlement agreements, Padagis will not be allowed to launch generic versions of QBREXZA, AMZEEQ and ZILXI until August 15, 2030, July 1, 2031 and April 1, 2027, respectively. Claude Maraoui, Journey Medical's Co-Founder, President and Chief Executive Officer, said, "These settlement agreements are an important step for Journey Medical, as they assist with solidifying our exclusivity and provide a clear pathway for years to come allowing us to grow the sales of our three newest products, QBREXZA, AMZEEQ and ZILXI. We believe in and will continue to enforce the intellectual property rights of our products. We believe that these settlements are beneficial to our company and shareholders, as well as prescribing physicians and their patients who depend on our novel products for treatment."

08:31 EDT Brandywine Realty commences 2340 Dulles Corner Boulevard redevelopment - Brandywine Realty Trust announces the commencement of a redevelopment project at 2340 Dulles Corner Boulevard in Herndon, Virginia in Metro DC, a 265,000 square foot office building that is currently vacant. The redevelopment is commencing with execution on an anchor lease from a leading telecommunications company for 221,000 square feet representing 85% of the property. The 11-year lease will commence upon tenant occupancy which is planned for Q2 2023. "We are delighted to announce that we have signed an anchor lease with a leading telecommunications company at our 2340 Dulles Corner Property," stated Gerard H. Sweeney, President, and Chief Executive Officer for Brandywine Realty Trust. "This redevelopment will bring an exceptional workplace experience to this growing company and is representative of forward-thinking companies' investment in people, culture, and brand."

08:30 EDT Regency Centers issues annual Corporate Responsibility Report - Regency Centers announced the release of its annual Corporate Responsibility Report. The report highlights Regency's 2021 environmental, social, and governance achievements and future commitments, and underscores its commitment to transparency in these crucial areas. "Corporate responsibility is embodied throughout our organization and is the lens through which we approach our business and make day-to-day decisions," said Lisa Palmer, President and Chief Executive Officer. "We have made great progress on our ESG initiatives over time, though there is still room to improve and elevate our commitments. I look forward to continue building on the momentum we've created."

08:29 EDT Melco Resorts & Entertainment releases 2021 sustainability strategy report - Melco Resorts & Entertainment has published its fourth sustainability strategy RISE to go Above & Beyond. "Through maintaining four key material topics that underpin Melco's sustainability commitment, including "Restoring our World", "Inspiring our Communities", "Sustaining our Supply Chain" and "Empowering our Business", the strategy drives performance and sustainability initiatives to help the Company reach its ambitious goals," the company said. Lawrence Ho, Chairman and CEO of Melco Resorts and Entertainment, said, "Melco has continued to rise beyond continuing pandemic challenges and in ways that have indeed accelerated our sustainability efforts in 2021. From colleagues to suppliers and partners, the Company is strengthening its actions to collectively address longer-term critical issues, including societal health, climate change and innovation. We continue to be determined to emerge from this pivotal moment in time, not as we were before, but by being more deeply aware of the needs of the world around us, and more purposeful in how business can meet those needs."

08:26 EDT Kratos Defense acquires Southern Research Engineering Division for $80M - Kratos Defense & Security Solutions announced that it has acquired the Birmingham, Alabama based Engineering Division of Southern Research for approximately $80 million, subject to reduction based on working capital, including $75 million in cash and $5 million in shares of Kratos common stock. Southern Research's Engineering Division is the market leader in assisting customers in the development, modeling and deployment of advanced materials for extreme environments, including hypersonic, space, missile, missile defense, strategic deterrence, propulsion systems, and energy applications. SRE also specializes in Intelligence Surveillance and Reconnaissance sensor development, electromechanical systems design and integration, aerospace engineering, materials engineering, artificial intelligence and machine learning, directed energy, RF systems design and integration, advanced manufacturing, and computational sciences. Approximately 25 percent of the SRE purchase price was paid for the one-of-a-kind, unique 54-acre campus, with 102,000 square feet of laboratory, material assessment, technology, prototype development, secure, and other facilities, and the machinery and equipment needed to perform the core, sole source test and evaluation analysis and extreme environment characterization of materials for Hypersonic, Missile Defense, Strategic Deterrent, Space-related and other Systems. The balance of the purchase price represents approximately 1.6 times SRE's historical, trailing twelve-month revenue, which includes approximately $15 million in annual ISR and other unique product development initiatives that are currently in development and expected to transition to production. The acquisition establishes Kratos SRE, a new business unit within Kratos' Defense and Rocket Support Services Division.

08:25 EDT Wayside's Climb Channel Solutions partners with Trilio - Climb Channel Solutions, wholly-owned subsidiary of Wayside Technology Group, and Trilio have announced a partnership to bring scalable Kubernetes backup, DR and management tools to organizations who are building cloud-native applications. Climb Channel Solutions' collaboration with Trilio will provide the solutions required to give businesses more power and control over their cloud and container environments. "Building a resilient cloud and container infrastructure is a priority for businesses in the ever-evolving IT data center," says Dale Foster, CEO of Climb Channel Solutions. "Partnering with Trilio will enable the channel to effortlessly scale and protect container environments. We look forward to a successful partnership."

08:23 EDT Egan Jones recommends Aerojet's stockholders to consent to special meeting - Eileen P. Drake, the CEO of Aerojet Rocketdyne, and the other members of the Committee For Aerojet Rocketdyne Shareholders and Value Maximization announced that Egan Jones has recommended that stockholders consent to the request of special meeting of stockholders sought by the Committee. Egan Jones is the third independent proxy advisory firm to recommend that stockholders "CONSENT" to the request of a special meeting sought by the Committee. As previously announced, Institutional Shareholder Services, or ISS, and Glass Lewis & Co. have also recommended that stockholders "CONSENT" to the request of a special meeting of stockholders.

08:21 EDT Rubius Therapeutics appoints Noubar Afeyan as chairman of the board - Rubius Therapeutics announced the appointment of Noubar Afeyan, Ph.D., co-founder and member of the board of directors of Rubius Therapeutics and chief executive officer of Flagship Pioneering, as chairman of its board of directors. David Epstein who has served as chairman since 2017 will remain a member of the board. Dr. Afeyan is founder and CEO of Flagship Pioneering, a company that conceives, creates, resources and develops first-in-category bioplatform companies to transform human health and sustainability. He is also co-founder and chairman of Moderna, the pioneering company of mRNA medicines which developed and supplied novel vaccine technology to address the global COVID-19 pandemic.

08:20 EDT Genocea announces wind down of operations, delisting from Nasdaq - Genocea Biosciences announced that its Board of Directors voted to wind down the Company's ongoing operations and terminate the Company's remaining employees except those deemed necessary to complete an orderly wind down. On May 23, 2022, the Company delivered formal notice to The Nasdaq Stock Market, Inc. of its intent to voluntarily delist its Common Stock from the Nasdaq Capital Market in connection with the wind down of its operations. The Company plans to file a Form 25 with the Securities and Exchange Commission on or about June 2, 2022, to effect the voluntary delisting of the Common Stock under Section 12(b) of the Securities Exchange Act of 1934, as amended. Also, on May 23, 2022, the Company received a letter from the Nasdaq Listing Qualifications department of Nasdaq notifying the Company that it was not in compliance with the requirement of Nasdaq Marketplace Rule 5450(a)(1) for continued inclusion on The Nasdaq Capital Market as a result of the closing bid price for the Company's common stock being below $1.00 for 30 consecutive business days.

08:19 EDT Sono-Tek expects double-digit year-over-year growth in Q1 - Fiscal 2023 sales are projected to reach record levels once again. The first quarter of fiscal 2023 is on track to generate double digit year-over-year growth, assuming we encounter no logistical shipping issues.

08:18 EDT FDA removes partial clinical hold on NEON-2 trial of ALPN-202 davoceticept combo - Alpine Immune Sciences announced that the U.S. Food and Drug Administration has removed the partial clinical hold placed on its NEON-2 trial evaluating davoceticept ALPN-202, a first-in-class conditional CD28 costimulator and dual checkpoint inhibitor, in combination with pembrolizumab in adults with advanced malignancies. The FDA removed the hold after review of the Company's Complete Response, which included a comprehensive review of the davoceticept safety database, as well as a revised investigator brochure and study protocol. As previously disclosed, under the terms of the hold, previously enrolled participants continued to receive study drug, but no new participants could be enrolled until the partial clinical hold was removed. The ongoing NEON-1 study was not subject to the hold.

08:17 EDT DigitalOcean announces new $300M share repurchase program - DigitalOcean announced that its board of directors has approved a new plan for the repurchase of up to an aggregate of $300M of its common stock. This plan is in addition to the $300M program that was announced in February and completed in May.

08:13 EDT Oportun Financial completes $400M asset-backed securitization - Oportun announced the issuance of $400 million of two-year revolving asset-backed notes secured by a pool of unsecured and secured installment loans. The offering included four classes of fixed rate notes: Class A, Class B, Class C and Class D. DBRS, Inc. rated all classes of notes, assigning ratings of A, A, BBB and BB, respectively. The Class A, Class B and Class C bonds were placed with a diversified mix of institutional investors in a private offering pursuant to Rule 144A under the Securities Act of 1933, as amended. The Class D bonds will be retained by an affiliate of Oportun. The Class A, Class B and Class C bonds were priced with a weighted average yield of 5.68% per annum. Jefferies LLC acted as the lead book runner with Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC as joint book-runners. Oportun will pledge the Class D bonds and the residual cash flows to its existing financing facility provided by Jefferies.

08:12 EDT NV5 Global awarded $8M in federal, state geospatial projects - NV5 Global announced that it has been awarded $8 million in recent contracts to provide geospatial data acquisition and data analytics services to support infrastructure, utility, and natural resource assets for public sector clients. NV5 was awarded two contracts totaling over $4 million to support the US Geological Survey's 3D Elevation Program in Kentucky and Wisconsin. The 3D Elevation Program's mission is to provide topographic data and three-dimensional representations of the Nation's natural and constructed features. The US Army Corps of Engineers selected NV5 for a $2 million task order to support the US Army Reserve's Installation Geospatial Information Services program. The IGI&S program provides a unified approach for the creation, maintenance, management, and delivery of military installation geospatial data. NV5 was also awarded a $2 million task order to support a federally owned electric utility's ongoing right-of-way program. NV5's contributions include the collection & analysis of geospatial data of the utility's bulk electric transmission system, providing the utility with a data-driven approach to managing risk while providing safe and reliable power to customers across the region.

08:11 EDT Petco jumps 5% to $15.35 after Q1 results top estimates

08:11 EDT CIM Commercial Trust announces $10M share repurchase program - CIM Commercial Trust announced that its board of directors authorized a repurchase program of up to $10M of the company's common stock.

08:10 EDT Malaysia Finance ministry awards digital banking license involving MoneyLion - MoneyLion announced that the Ministry of Finance in Malaysia has awarded a digital banking license to a consortium involving MoneyLion, AEON Financial Service a Japan-based financial group, and AFS's Malaysia-based non-bank financial service provider subsidiary, AEON Credit Service Berhad. MoneyLion is launching a Software-as-a-Service offering to develop the digital platform and provide technology, data analytics and embedded finance capabilities to the consortium. For nearly a decade, MoneyLion has been building financial technology that empowers consumers to take control of their financial lives through powerful products that make it easier to borrow, save, invest and earn. MoneyLion's platform offers an engaging user experience delivering daily curated content designed to educate consumers on how to best achieve their financial goals. MoneyLion's technology and analytics capabilities also include underwriting, pricing risk and originating credit, at scale. As a result of this experience, MoneyLion's technology, artificial intelligence and data analytics capabilities have compounded over time to create an industry-leading data advantage with enterprise-ready SaaS applications that will diversify its revenue streams and position the company for further growth. The digital banking license will give MoneyLion, AEON Credit and AFS the ability to create a digital bank that will offer services which will promote financial inclusion to customers in Malaysia. MoneyLion will be responsible for designing and building the bank's digital finance platform using its scaled technology and data capabilities. MoneyLion has a significant presence in Malaysia, employing around 300 engineers and data scientists in Kuala Lumpur that develop both the interface and underlying technology powering the award-winning MoneyLion app, catering to millions of users in the United States.

08:09 EDT Natera appoints Minetta Liu as Chief Medical Officer of oncology - Natera announced the appointment of Minetta Liu, as its new Chief Medical Officer of oncology. In this role, Liu will set the direction for the company's clinical and scientific roadmap in oncology, primarily to prove the clinical utility of Signatera and incorporate it into standard medical practice across tumor types. Liu most recently served as professor of oncology and chair of research in the Department of Oncology at Mayo Clinic in Rochester, MN. In her role at Mayo, she also held a dual appointment in the Department of Laboratory Medicine and Pathology and served as co-leader of the Genomics in Action Strategic Priority for the Center of Individualized Medicine. In her new position as CMO, Liu will succeed Alexey Aleshin, who was recently appointed Natera's general manager of early cancer detection.

08:08 EDT Splash Beverage signs distribution agreement with Buck Distributing - Splash Beverage Group announced that it has signed a distribution agreement with Buck Distributing in Maryland to distribute all Splash Beverage Group products through 5 Central Maryland Counties. Buck Distribution is a malt beverage and related products distributor headquartered in Upper Marlboro, Maryland. "This agreement continues our streak of landing significant distribution agreements with major regional players," said Robert Nistico, Splash Beverage Group's Chairman and CEO. Buck Distribution has been a 3-time winner of the prestigious Miller Masters award and a 4 time winner of the MillerCoors Presidents award. They've been distributing for Miller Beer since 1952 and for Molson Coors since 1972. All four of our main beverages, TapouT, Copa di Vino, SALT Tequila and Pulpoloco Sangria will now be available through the Buck system, which has a long history of high-quality, value-added service and we're delighted to be working with them."

08:07 EDT electroCore announces gammaCore Sapphire nVNS available through NSPC - electroCore announced that the gammaCore Sapphire non-invasive vagus nerve stimulator, nVNS, will be available for purchase through many of the more than 130 National Spine and Pain Centers, NSPC, affiliated locations across the United States for patients suffering from pain associated with different forms of primary headache. "We are excited to be working with National Spine and Pain Centers as we expand patient access to our therapy," commented Mitch DeShon, electroCore's Vice President of US Sales. "NSPC is one of the Company's first corporate accounts and serves as an example of how national healthcare organizations and electroCore could work together to expand adoption of gammaCore nVNS for sufferers of primary headache, and reinforces the Company's strategy of providing patients with greater access to our nVNS therapy through healthcare providers or directly via our online stores."

08:06 EDT Honeywell to help customers achieve carbon neutrality - Honeywell announced an Emissions Control & Reduction Initiative designed to help customers achieve carbon neutrality in a wide range of areas. The initiative will initially focus on helping oil and gas customers with upstream, midstream and downstream operations to monitor and reduce fugitive methane emissions, which are more than 25 times as potent as carbon dioxide at trapping heat in the atmosphere according to the Environmental Protection Agency. By combining its portfolio of fixed, portable and personal gas detection solutions with gas cloud imaging cameras, Honeywell will provide customers with early detection of fugitive methane emissions, including the precise location of any leaks and associated data analytics and trends. Equipped with this data, users can act quickly to address leaks and other identified risks to minimize production losses and maintain compliance with legislation. Honeywell's methane detection capability will be available to customers in Q4 2022.

08:06 EDT Ralph Lauren increases quarterly cash dividend 9% to 75c per share - The company also announced that its board of directors declared a 9% increase in the regular quarterly cash dividend on the company's common stock. The new quarterly cash dividend is 75c per share for a total annual dividend amount of $3.00 per share. The next quarterly dividend is payable on July 15 to shareholders of record at the close of business on July 1.

08:05 EDT Teledyne gets $14M contract for Black Hornet Nano-UAV Systems for U.S Army - Teledyne FLIR Defense, part of Teledyne Technologies has won another $14 M contract to deliver its Black Hornet 3 Personal Reconnaissance Systems to the United States Army. The advanced nano unmanned aerial vehicles are being used to augment squad and small unit-level surveillance and reconnaissance capabilities as part of the Army's Soldier Borne Sensor program. "The Black Hornet is one tough small package with tremendous capabilities that gives warfighters much needed situational understanding and standoff before undertaking dangerous operations," said Dr. JihFen Lei, executive vice president and general manager of Teledyne FLIR Defense. "We are proud to support the Army's Soldier Borne Sensor program for more than three years and will continue to invest in nano-UAS technologies that are changing today's battlefield."

08:04 EDT Brookline Bancorp to acquire PCSB Financial for $313M in cash, stock - Brookline Bancorp and PCSB Financial Corporation announced they have entered into a definitive merger agreement whereby Brookline will acquire PCSB and its wholly owned subsidiary, PCSB Bank for approximately $313 million in cash and stock. Following the transaction, PCSB Bank will operate as a separate bank subsidiary of Brookline. Under the terms of the merger agreement, stockholders of PCSB will receive, for each share of PCSB, at the holder's election, either $22.00 in cash consideration or 1.3284 shares of Brookline common stock for each share of PCSB common stock, subject to allocation procedures to ensure 60% of the outstanding shares of PCSB common stock will be converted to Brookline common stock. The receipt of Brookline common stock by stockholders of PCSB is expected to be tax-free. The transaction is presently valued at approximately $313 million in the aggregate, or approximately $20.72 per PCSB share, based on Brookline's common stock price of $14.96 at close on May 23rd, 2022. Anticipated double-digit EPS accretion of approximately 13% to Brookline's earnings per share, excluding the impact of expected revenue enhancement opportunities. Expected IRR of approximately 15%, exceeding Brookline's cost of capital. Pro forma capital ratios of 8.6% TCE/TA and 13.0% Total Risk-Based Capital Ratio, estimated at close. Combined company total assets of $10.6 billion, loans of $8.5 billion, and deposits of $8.7 billion. The combined organization will further establish Brookline as a premier commercial banking franchise in the Northeast with over $10 billion in assets, and will represent one of the few regional banks operating in the Boston, Providence and New York metropolitan markets. Brookline and PCSB have complementary business models focused on relationship-based CRE and C&I lending, which include an extensive suite of financial products and services. Upon completion of the merger, PCSB Bank will retain its New York bank charter and Board of Directors and its headquarters will remain in Yorktown Heights. Brookline will select one PCSB director to join its Board of Directors. In addition, following the closing, Michael P. Goldrick, currently PCSB Bank's Executive Vice President and Chief Lending Officer, will become PCSB Bank's President and Chief Executive Officer. The transaction has been unanimously approved by the Board of Directors of both companies and is expected to be completed in the second half of 2022, subject to approval by PCSB stockholders, as well as regulatory approvals and other customary closing conditions.

08:03 EDT HomeTrust announces Westbrook to succeed Stonestreet as CEO - The Board of Directors of HomeTrust Bancshares announced that effective September 1, 2022, C. Hunter Westbrook will succeed Dana Stonestreet as Chief Executive Officer of the Company and continue his leadership of HomeTrust Bank as President and Chief Executive Officer. Stonestreet, who has been with HomeTrust for 33 years and as Chairman and CEO since 2013, will become the Executive Chairman of the Company and Bank. Stonestreet has coordinated with the Board of Directors in preparation for his future retirement.

08:01 EDT Jacobs selected by McConnell Dowell for bridge project in Tasmania - Jacobs was appointed design consultant by McConnell Dowell to provide detailed design services for the New Bridgewater Bridge project in Hobart, Tasmania. A significant transport infrastructure project for the region, the new bridge will make travel safer and more efficient for thousands of commuters each day and deliver a wide range of socio-economic benefits. Part of the Hobart City Deal, the 10-year framework to guide and encourage further investment in the city, the Tasmanian government estimates the project value to be $566M. Major construction is set to begin in mid-2022 with traffic planned to travel over the new bridge by the end of 2024.

07:56 EDT PCSB Financial trading halted, news pending

07:47 EDT Allied Properties Real Estate appoints Hazel Claxton to board - Allied Properties Real Estate Investment Trust announced that Hazel Claxton has been appointed as a trustee of Allied by the Trustees. She will hold office as a Trustee until the next annual meeting of unitholders or until her successor is elected or appointed. Hazel Claxton is a corporate director. She served as Executive Vice-President and Chief Human Resources Officer with Morneau Shepell from 2013 to 2018.

07:43 EDT Knight Therapeutics enters license, supply agreements with Rigel - Knight Therapeutics entered into exclusive license and supply agreements with Rigel Pharmaceuticals granting Knight the rights to commercialize fostamatinib, an oral spleen tyrosine kinase inhibitor, in Latin America. Fostamatinib is commercially available in the United States under the brand name TAVALISSE and in Europe under the brand name TAVLESSE for the treatment of chronic immune thrombocytopenia. Fostamatinib is also currently being studied in a Phase 3 clinical trial for the treatment of warm autoimmune hemolytic anemia and in two Phase 3 clinical trials for the treatment of hospitalized patients with COVID-19. Under the terms of the agreement, Rigel will receive an upfront cash payment, with the potential for additional regulatory and commercial milestones, and stepped-up royalties based on tiered net sales. In return, Knight receives exclusive rights to fostamatinib in all potential indications, including chronic ITP, wAIHA, and COVID-19 in Latin America.

07:39 EDT Aerie doses 1st person for 'COMET-2' study AR-15512 ophthalmic solution for DED - Aerie Pharmaceuticals announced that the first participant has been dosed in the Phase 3 registrational "COMET-2" study to evaluate AR-15512 ophthalmic solution as a treatment for the signs and symptoms of dry eye disease . COMET-2 is the first of three trials in the Phase 3 registrational program for AR-15512. Aerie plans to initiate the other two trials in the second half of 2022 in support of a potential New Drug Application filing in 2024. COMET-2 is a randomized, double-masked, vehicle-controlled, multi-center clinical study to evaluate the efficacy and safety of AR-15512, a TRPM8 agonist, in patients with DED. The study is expected to enroll approximately 460 participants at 20 U.S. sites. Study participants will receive AR-15512 or AR-15512 vehicle as a drop dosed twice daily in each eye for three months. The primary efficacy assessment is tear production, as measured by the unanesthetized Schirmer test and the key secondary measure is dry eye symptoms based on the Symptom Assessment iN Dry Eye questionnaire. Participants will be evaluated on multiple efficacy and safety assessments at multiple timepoints throughout the study. Topline results from the COMET-2 study are expected in the second half of 2023. Dr. Senchyna continued, "There is a significant unmet need for an effective treatment that can provide a rapid and robust onset of efficacy, and meaningful relief of dry eye symptoms. AR-15512 has the potential to be the new standard of care for patients suffering from dry eye disease."

07:39 EDT Aleafia Health provides update on market share rankings - Aleafia Health is pleased to announce that its upward trend in market share, purchase orders, and new SKU launches has continued in 2022's first four months, following on from the growth in the quarter ended December 31, 2021. The Company has seen strong advances in its largest adult-use categories: flower, pre-rolls and vapes. The Company has now achieved more than four consecutive quarters of increases in adult-use cannabis market share, rising to 2.5% in April 2022, a 134% year over year increase over April 2021. Among Canadian licensed Cannabis producers, Aleafia Health achieved a record 13th in overall market share rank in April 2022, based on retail level sales pull through, up from 16th in the quarter ended December 31, 2021. At the Ontario Cannabis Store, sales for the recently launched Pineapple Nuken pre-roll 12 pack exceeded $1 million in the first four months of 2022 and sales of cropped harvest products were nearly $1 million in their first month. "On our Q4 2021 earnings call earlier this year, we committed to delivering on ambitious growth plans and the Company is now meeting and, in some cases, exceeding those targets," said Aleafia Health's CEO Tricia Symmes. "The Company has a superb, hard-working team, and strong consumer acceptance for its Sunday Market house of brands. It's no wonder that our everyday brand Divvy has been among the OCS' most searched product list for the last 14 months. It's a very exciting time for the Company as quarter by quarter we build on our foundation and get increasingly more recognition among savvy industry participants who recognize we are here to compete. By strategically creating a portfolio of 37 active SKUs in the OCS, with 12 additional SKUs launching in the Spring and Summer, we are laser focused on the largest margin, top revenue-generating product categories: flower, pre-roll and vapes, with 67% of our SKU listings in those categories," said Symmes. "In AGLC we have 43 active SKUs, with 8 SKUs pending launch, and in that market 60% of our SKU listings are in those same three large product categories."

07:34 EDT PyroGenesis announces project with leading furnace manufacturer - PyroGenesis Canada announces that, further to its press release dated April 20th, which provided an update on its Aluminum Business offerings, the Company has undertaken a joint evaluation with a major manufacturer, to test PyroGenesis' zero-emission plasma torches in their scrap remelting and holding furnaces for the aluminum industry. The name of the Client remains anonymous for confidentiality reasons. This Agreement outlines, amongst other things, the first step being a computational fluid dynamics, CFD, study to gather pre-test data and evaluate plasma for use in furnaces serving the secondary aluminum market: i.e., aluminum producers who re-melt and re-sell scrap and recycled aluminum. PyroGenesis has already received a purchase order for the CFD study which is well underway, and additional next steps are already being planned. "This Agreement underscores the applicability, and timing, of PyroGenesis' offerings within the aluminum industry which, incidentally, has now expanded beyond just primary aluminum producers," said P. Peter Pascali, CEO and Chair of PyroGenesis. "This is particularly interesting given this Agreement is, once again, with such a prominent manufacturer in the industry."

07:28 EDT Guardforce AI to acquire eight companies in China for $30M - Guardforce AI announced it has entered into two definitive agreements to acquire a total of eight companies in China. The first agreement is to acquire Beijing Wanjia Security System Limited, an integrated security provider with 25 years of experience from Shenzhen Yeantec Co., Limited for approximately $8.4M. The acquisition is expected to close in June 2022, subject to customary closing conditions. The second agreement is to acquire an additional seven companies from Shenzhen Kewei Robot Technology, valued at approximately $21.6M, which acquisition is expected to close in the third quarter of 2022. The seven companies include: Beijing Keweian Robot Technology Limited, based in Beijing; Shanghai Nanxiao Kewei Intelligent Technology Limited, based in Shanghai; Tianjin Kewei Robot Technology Limited, based in Tianjin; Chongqing Kewei Robot Technology Limited, based in Chongqing; Guangxi Kewei Robot Technology Limited, based in Nanning, Guangxi Province; Fuzhou Kewei Robot Technology Limited, based in Fuzhou, Fujian Province; Hainan Kewei Robot Technology Limited, based in Haikou, Hainan Province. The seven companies to be acquired from Kewei are established providers of Robotics-as-a-Service solutions in their respective markets in China. During the past several years, these companies have expanded their customer base across various industries, such as hospitality, healthcare, education, malls, and property management. The total deal value of both acquisitions of $30M is based on one-time projected average revenues for the eight companies over the next 5 years. The deal will be paid in a combination of cash and restricted ordinary shares of the Company at the previously agreed price of U.S. $2.00 per share.

07:23 EDT Timbercreek Financial announces normal course issuer bid - Timbercreek Financial announced that it has obtained the approval of the Toronto Stock Exchange to commence a normal course issuer bid (the "NCIB") with respect to its common shares. The NCIB will commence on May 26, 2022 and will terminate on the earlier of May 25, 2023 or the date on which the Company has purchased the maximum number of Shares permitted under the NCIB. Under the NCIB, the Company may, over a 12-month period commencing on May 26, 2022, purchase in the normal course through the facilities of the TSX in accordance with its rules or through alternative Canadian trading platforms up to a regulatory maximum of 8,330,591. Shares, such amount representing 10% of the public float of the Shares issued and outstanding as of May 17, 2022. Furthermore, subject to certain exemptions for block purchases, the maximum number of Shares that the Company may acquire on any one trading day is 30,366 Shares, such amount representing 25% of the average daily trading volume of the Shares for the six calendar months prior to the start of the NCIB, being 121,465 Shares. As of May 17, 2022, there were 83,952,432 Shares issued and outstanding. Under the normal course issuer bid which commenced on April 15, 2021 and terminated on April 14, 2022, the Company was authorized to purchase up to 8,030,909 Shares but did not make any purchases during that time.

07:19 EDT Rubicon Organics expects to be Adjusted EBITDA profitable in 2022 - The company said, "In the fourth quarter of 2021, Rubicon Organics defined a three-pillar strategy for 2022 focused on yield and quality, improving product mix to optimize margin, and launching international products, each of which we expect will have a positive impact on our profitability and cashflow. This strategy remains in place and the Company is having positive trajectory on each of the pillars. Our first pillar is to optimize production processes at the Delta Facility to increase yield and THC of our super-premium cannabis. We have completed facility upgrades, invested in process improvements, and continue to identify opportunities for cost efficiencies. The Company installed new climate control systems, most critical being the dehumidification units, and refined its cultivation system, which has allowed us to reach an annualized production rate of 9,000 kg's as at the end of the first quarter 2022. In the first quarter of 2022 we have seen our average THC increase significantly, with certain strains as high as 29% THC. Maintaining high quality flower with greater THC content from each crop continues to be a priority and we anticipate our improved product offerings to enter the market in the second quarter. Our Delta Facility is expected to also benefit from the upgrade to the BC Hydro grid resulting in further production cost savings in the second half of 2022. The second pillar is to implement our commercial strategies within the Canadian domestic market to maximize the gross profit for each unit produced from our Delta Facility which, coupled with delivering increased quality of flower and higher THC, is expected to drive more volume into our Simply Bare(TM) Organic and 1964 Supply Co(TM) brands. During the first quarter of 2022, the Company maintained significant market share in the premium and organic product categories with its Simply Bare(TM) Organic brand capturing 7.1%5 of the premium flower and pre-roll market. We grew revenue 25% year over year compared to the same quarter in 2021. While January sales were weaker than in the fourth quarter of 2021 with the effects of 'dry January', thereafter the Company's revenue returned to more normalized patterns in February and March. In the first quarter of 2022 we now have the full suite of Rubicon brands in market and invested behind them to ensure that we are able to launch innovation at different price segments to satisfy consumer preferences. In line with our strategy, we have seen the sales of 1964 Supply Co(TM) increase by 141% as compared to the same three month period in 2021. 1964 Supply Co(TM) has made significant gains in the BC marketplace and we expect the brand to become a mainstream category leader. The premium cannabis market is gaining momentum and outpacing the growth of the total market6 and this is expected to benefit the premium product innovations we are bringing to the market. 2022 is expected to be the first full year with all five of Rubicon's wholly owned and licensed brands in market with national distribution. Future line extension and innovation in flower, pre-roll and 2.0 products are expected to be launched under the existing brand portfolio. Our third pillar is to open the routes to market for our products internationally by obtaining key certifications and agreements to launch into Israel and Europe, with our first exports expected to occur in the second half of 2022. The IMC-G.A.P. certification received May 2022 is one of the key milestones to delivering to certain international markets. The Company also expects to receive its EU-GMP certification in 2022 allowing for export of finished goods to the European market. Rubicon believes that the combination of new brands in key Canadian markets and increased product offerings enable us to capitalize on our momentum and, coupled with a continued increase in production quality and yield, we expect strong topline and margin growth in 2022. We continue to believe that the cannabis sector will have significant volatility in 2022 as there are ongoing changes in the retail stores environment, provincial mandates, and increased competition. With the COVID-19 wave in the first quarter we experienced staff shortages at our facility and lower than forecast demand in January and February which we believe is attributed to seasonality and changing COVID mandates for access to Quebec stores. In March we saw a return to our previously anticipated sales levels. Notwithstanding this volatility, with our current trajectory of increased supply we expect to able to sell everything we cultivate to either domestic or international market demand during 2022. From a capital management perspective, Rubicon intends to extend its existing debt facility or find a new facility at similar rates to keep cash optionality in the business. The Company performed a cost review in the first quarter of 2022 to drive the business towards profitability as quickly as possible and expects to be able to maintain a lower cost structure while still delivering on forecasted revenues. The Company achieved positive operating cashflows for the first time in the fourth quarter of 2021. The Company's current expectation is to be operating cashflow positive and Adjusted EBITDA profitable in 2022. We believe that despite any market volatility 2022 our focus on our three pillars coupled with our brand portfolio expansion achieved in 2021 will position Rubicon to continue to deliver on its commitments and win in the premium market."

07:17 EDT Ocugen announces cell therapy program after FDA RMAT designation for NeoCart - Ocugen announced that it is diversifying its innovative pipeline by introducing a Phase 3, cell therapy platform technology called NeoCart. Recently, the U.S. Food and Drug Administration, FDA, granted a Regenerative Medicine Advanced Therapy, RMAT, designation to NeoCart for the repair of full-thickness lesions of the knee cartilage in adults. "We're excited that NeoCart has received this RMAT designation, an important regulatory milestone, especially as we view this product as an enabling technology in cell and regenerative therapy for orthopedic indications. Our next step will be working with the FDA to construct the Phase 3 program to bring this innovation to this emerging treatment area," said Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder, Ocugen, Inc. "People living with articular cartilage lesions literally have holes in their knees that are extremely difficult to heal, and without proper treatment, they're at high risk of getting osteoarthritis. We believe that NeoCart offers the potential for an innovative new option where treatments in this area are still limited and results are not optimal." Ocugen is working with the FDA to finalize the Phase 3 protocols necessary to advance the clinical development program of NeoCart required for eventual market authorization.

07:16 EDT Arena Minerals enters collaboration agreement with Lithium Americas - Arena Minerals is pleased to announce it has entered into a Pastos Grandes Technical Collaboration Agreement with Lithium Americas. The intention of the Collaboration Agreement is to share technical information and explore opportunities for collaborating on potential development alternatives with the overall objective of optimizing the production profile of the Pastos Grandes basin. The Collaboration Agreement shall be governed by a technical committee comprising three members nominated by Lithium Americas, and three members nominated by Sal de la Puna Holdings which is jointly owned by Arena and Ganfeng New Energy Technology Development. The Technical Committee will consider ways in which the parties can exchange information and ideas and otherwise collaborate to expand the knowledge of the parties regarding the geology and hydrogeology of the Pastos Grandes basin and the technical aspects of extracting, concentrating and processing brine to produce lithium products from their respective properties. These include: Exploring and developing optimal processing technologies, including: production of 35% lithium chloride directly from ponds, without the construction of a carbonate plant, production of lithium carbonate from 35% lithium chloride vs using a liming process with the construction of an on-site carbonate plant; and potential alternative direct lithium extraction technologies; Developing a basin-wide resource model, including a dynamic hydrogeological model and water resources/sources model; Developing an optimal brine production model from the combined tenements of SdlPH and Lithium Americas in Pastos Grandes, integrated with the basin-wide model and brine resources; and The coordination of any joint presentations and reports the parties agree to make together to the mining, environmental and water authorities, communities and any related stakeholder to the parties' respective project. Information to be shared includes environmental baseline data, drill hole and sampling databases, processing methodologies and concentration paths, and existing extractive model, including resource and dynamic brine models. However, neither LAC, Arena or SdlPH will provide, transfer, grant or license any intellectual property to the other, including patents, inventions and know-how, and neither party will acquire any interest in intellectual property owned by the other party. This includes Arena's proprietary process aimed at producing 35% lithium chloride from evaporation ponds. The provision of such information is governed by a confidentiality agreement between the parties which agreement contains specifics respecting the information to be shared by the parties and provides that the disclosure of information is subject to the discretion of each of Lithium Americas and SdlPH. The Collaboration Agreement also includes the common use of infrastructure owned by both companies, so long as the use does not interfere with the operation of the respective projects. The infrastructure includes a fully equipped on-site analytical laboratory, pilot ponding facilities, a pilot carbonate conversion plant, and ancillary camp infrastructure. The first Technical Committee meeting has taken place, during which Lithium Americas and SdlPH set committee members, coordinated sharing of data, discussed infrastructure access and requirements, and approved the sharing/use of environmental baseline studies. Further initiatives were also discussed, including processing paths and development initiatives. Further work will be disclosed as available. Arena Minerals Inc also announces the appointment of Xiaofeng Luo as a Non-Executive Director of the Board nominated by Ganfeng Lithium Inc., with effect from May 24, 2022, replacing Sam Pigott, who has resigned from the Board of Arena Minerals on the same date. Xiaofeng Luo is President and CEO, Litio Minera Argentina and Ganfeng Litio Argentina, both 100% owned subsidiaries of Ganfeng Lithium and serves as Ganfeng Lithium's representative on the SDLP Technical Committee.

07:12 EDT Lithium Americas announces commencement of trading on TSX Venture Exchange - Lithium Ionic announces that the Company's common shares will commence trading on the TSX Venture Exchange at the opening of market on Tuesday, May 24, 2022 under the symbol "LTH". Blake Hylands, Chief Executive Officer of Lithium Ionic, comments, "We are very excited to commence trading on the TSX Venture Exchange. We look forward to presenting great results in the coming weeks and months. Our Itinga Lithium project is well situated directly between the CBL Lithium Mining operation to the northwest and Sigma Lithium's project to the southeast. Trenching and diamond drilling has already commenced on the Itinga project, and our team has already identified good grade lithium mineralization in trenches. The initial trench exposed 8.8 meters grading 1.46% Li2O including 5.8 meters grading 1.82% Li2O."

07:12 EDT OceanFirst Financial publishes first ESG report - OceanFirst Financial, the holding company for OceanFirst Bank, announced that the Bank has published its first-ever Environmental, Social and Governance, ESG, Report. The ESG Report highlights the Bank's policies, practices and recent initiatives across a range of areas, including equitable access to capital; diversity, equity and inclusion; employee health and wellness; support for the community; environmental priorities; corporate governance; and other vital matters. "We are proud to announce the first formal ESG Report for OceanFirst is now available on our website, while noting that our commitment to serve all of our stakeholders in a responsible manner dates back more than a century, reflecting our strong roots as a community banking organization," said Christopher Maher, Chairman and Chief Executive Officer. "As our society and economy experience dramatic changes, we believe that companies must demonstrate leadership in a wide range of areas broadly known as ESG. At OceanFirst, we are acutely aware of the vital importance of maintaining responsible ESG policies and practices - to serve the interests of our stakeholders; expand access to economic opportunity; protect our enterprise from external risks; and fulfill our responsibilities to our communities, society and planet," Maher added.

07:09 EDT Equifax appoints Kyriakatos as Chief Data Officer - Equifax Canada has appointed Sandy Kyriakatos to the position of Chief Data Officer, with a mandate of advancing Equifax's data strategy to benefit customers and consumers alike. Before joining Equifax, Kyriakatos was the first Chief Data Officer in the Canadian public services, having held the role with the Canada Border Services Agency as well as Employment and Social Development Canada.

07:08 EDT Houston American Energy begins drilling on the CPO-11 Venus Exploration Area - Houston American Energy announced that final approvals and permits have been received and drilling operations have commenced on a well on the CPO-11 Venus Exploration Area in Colombia. The well, operated by Hupecol Operating, is Houston American's first well to be drilled on the 69,128 gross acre Venus Exploration Area. The Venus Exploration Area, and a 50% interest in the larger CPO-11 block, are held by Hupecol Meta. Houston American, through its ownership interest in Hupecol Meta, holds a 6.99% working interest in the subject well and Venus Exploration Area.

07:06 EDT Chevron, Talos Energy, Carbonvert close JV expansion of Bayou Bend CCS project - Chevron (CVX), through its Chevron New Energies division, Talos Energy (TALO), through its Talos Low Carbon Solutions division, and Carbonvert announced the execution of definitive documentation and closing of the expanded joint venture to develop the Bayou Bend CCS offshore carbon capture and sequestration hub, effective May 1. Under the terms of the transaction, Chevron has acquired a 50% stake in the expanded Bayou Bend CCS joint venture for gross consideration of $50M to Talos and Carbonvert, consisting of $30M of gross upfront cash and up to $20M of gross capital cost reimbursement, expected to cover Talos and Carbonvert capital expenditures through the project's final investment decision. Equity interests in the joint venture are now 25% Talos, 25% Carbonvert, and 50% Chevron, and Talos is the operator. The three companies have also established an Area of Mutual Interest over the full ~231,000-acre Jefferson County offshore region contemplated in the State of Texas's original request for proposal, aligning the parties for future expansion opportunities.

07:05 EDT Else Nutrition completes initial commercial production of infant formula - ELSE NUTRITION HOLDINGS announces that it completed initial commercial production in April of its infant formula, to be used in key Clinical Studies for the U.S. market. Following the commercial production, Else will conduct clinical trials to validate product safety and benefits for regulatory approval of its infant formula, which is anticipated to become the Company's flagship product. This Plant-Based formula results from many years of development of a unique proprietary scientific process to ensure that it meets U.S. and global regulations and clinical requirements for infant nutrition which is clean of impurities, certain trace elements and reduces mineral levels that exceed maximum allowed. The Company mandatorily developed this new patent protected processes to ensure the product adheres to Else's core values meets the stringent FDA and European standards, and still brings the best-in-class product to market.

07:03 EDT Casi signs sublicense agreement with Beijing Tianshi Tongda for anti-CD38 - CASI Pharmaceuticals announced the signing of a Sublicense Agreement with Beijing Tianshi Tongda Pharmaceuticals Technology a clinical stage pharmaceutical company organized and existing under the laws of the People's Republic of China. The Sublicense Agreement grants TIANSHI an exclusive, perpetual, worldwide license for the investigational anti-CD38 monoclonal antibody, CID-103, in the treatment, prevention, and diagnosis of autoimmune diseases, conditions, and disorders in humans. Under the terms of the agreement, CASI shall maintain the exclusive commercialization and co-marketing rights of CID-103 in autoimmune indications and book all revenue in the United States. CASI has the co-commercial rights in autoimmune-derived hematology and oncology indications of CID-103 in China, but not obligated to co-commercialize those programs. As part of the agreement, TIANSHI agreed to pay CASI a $10M upfront payment in two instalments, as well as certain future milestone and royalty payments. Following the execution of this agreement, TIANSHI will complete its first equity financing. Upon completion of such equity financing, CASI, through its wholly-owned PRC subsidiary, will hold 15% equity of TIANSHI, which is expected to receive 120M RMB from two venture capital investors and 20M RMB from CASI Pharmaceuticals.

07:02 EDT Omnicom names Brian Clayton as Chief Data Privacy Officer - Omnicom Group (OMC) announced the appointment of Brian Clayton, Chief Data Privacy Officer. In this new role, Clayton will be responsible for driving Omnicom's privacy first approach while ensuring brands and the company comply with the increasingly complex data privacy laws and regulations around the globe. Clayton comes to Omnicom from Conduent (CNDT), a former Xerox (XRX) company, where he was Associate General Counsel and Chief Privacy Officer overseeing data privacy and compliance for more than 65,000 employees in over 70 countries.

06:57 EDT AutoZone opened 24 new stores in the U.S. in Q3 - During the quarter ended May 7, AutoZone opened 24 new stores in the U.S., opened four stores in Mexico and three stores in Brazil. As of May 7, the company had 6,115 stores in the U.S., 673 in Mexico and 58 in Brazil for a total store count of 6,846.

06:55 EDT Piedmont's partner publishes prefeasibility study to restart operations at NAL - Piedmont Lithium announced that Piedmont's partner, Sayona Mining, recently published a prefeasibility study for the restart of spodumene concentrate operations at the North American Lithium Project in Quebec, or NAL. The NAL PFS contemplates average annual production of approximately 168,000 tonnes per year of 6% spodumene concentrate over a mine life of 27 years. The NAL Study highlights estimated competitive cash operating costs and an estimated capital cost for the mine and concentrator restart of approximately $80M. Piedmont and Sayona acquired the previously-producing NAL operations in August 2021. Following the positive results of the NAL Study, the partners expect to proceed with full capital expenditure authorization. According to Sayona's study results, operations could recommence in the first half of 2023. Importantly, the NAL Study has identified a number of de-bottlenecking and process improvements within the spodumene concentrator which will improve operational availability, lithium recovery, and product quality. Piedmont owns a 25% project interest in the NAL and Authier Projects via its equity stake in Sayona Quebec as well as its equity interest of approximately 16.5% in Sayona Mining. With the publication of the NAL PFS, Piedmont will now begin to explore marketing options for its share of spodumene concentrate production contemplated in its offtake agreement with Sayona, which provides Piedmont with the right to purchase the greater of 50% of production or 113,000 metric tonnes per year from the NAL Project.

06:48 EDT Merck: EC approves KEYTRUDA plus chemotherapy for treatment of TNBC - Merck announced that the European Commission has approved KEYTRUDA, Merck's anti-PD-1 therapy, in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery for adults with locally advanced or early-stage triple-negative breast cancer at high risk of recurrence. The approval is based on results from the pivotal Phase 3 KEYNOTE-522 trial, in which KEYTRUDA in combination with chemotherapy before surgery and continued as a single agent after surgery prolonged event-free survival, reducing the risk of EFS events or death by 37% compared to neoadjuvant chemotherapy alone in this patient population. Median follow-up time for all patients was 37.8 months.

06:34 EDT VIA Optronics announces continued growth at corporate headquarters - VIA optronics announced that the growth of its corporate headquarters and production site in Nuremberg, Germany now exceeds 200 employees as the company makes progress towards finalizing the ongoing production ramp up. In 2021, VIA added a new production building adjacent to its headquarters and started ramping up mass production in its automotive production line, which the company expects to reach the planned capacity during the second quarter. The company has added staff in critical areas such as engineering, quality control, supply chain management and production. As previously announced, in the initial production phase of its automotive production line, VIA optronics will be able to produce approximately 10,000 display units per month. The initial production phase is dedicated completely to a leading U.S. based luxury electric vehicle manufacturer. The total capacity at the Nuremberg facility is approximately 60,000 product units per month, depending on the product size and type.

06:32 EDT SpringsWorks Therapeutics: Nirogacestat achieved endpoints in Phase 3 DeFi trial - SpringWorks Therapeutics announced positive topline results from the DeFi trial, a double-blind, placebo-controlled Phase 3 trial evaluating the efficacy, safety and tolerability of nirogacestat, an investigational oral gamma secretase inhibitor, in adult patients with progressing desmoid tumors. The DeFi trial met its primary endpoint of improving progression-free survival, demonstrating a statistically significant improvement for nirogacestat over placebo, with a 71% reduction in the risk of disease progression. In addition, the trial met all key secondary endpoints, with nirogacestat demonstrating statistically significant improvements as compared to placebo in objective response rate and patient-reported outcomes. Nirogacestat was generally well tolerated with a manageable safety profile. The majority of women of childbearing potential had adverse events consistent with ovarian dysfunction. Other adverse events were generally consistent with previously reported data. Additional data are expected to be presented at an upcoming medical conference in the second half of 2022 and SpringWorks plans to submit a New Drug Application to the U.S. FDA in the second half of 2022.

06:11 EDT Honeywell committed to deploying $25B+ over next three years - Sees $4B in share repurchases in 2022.

06:08 EDT Amphastar receives FDA approval for Regadenoson injection ANDA - Amphastar announced that the FDA has approved the company's abbreviated new drug application, or ANDA, for Regadenoson injection, 0.08 mg/mL, 5mL Single Dose Pre-Filled Syringe. Regadenoson is indicated for radionuclide myocardial perfusion imaging, or MPI, in patients unable to undergo adequate exercise stress. The FDA determined that Amphastar's regadenoson is bioequivalent and therapeutically equivalent to Astellas Pharma U.S., Inc's Lexiscan.

06:05 EDT MannKind's Technosphere inhalation platform utilized in FDA-approved Tyvaso DPI - MannKind (MNKD) celebrated that the U.S. FDA has approved United Therapeutics' (UTHR) Tyvaso DPI inhalation powder for the treatment of patients with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Tyvaso DPI represents the second FDA-approved product utilizing MannKind's innovative Technosphere inhalation technology and is the first and only approved dry powder inhaled treatment for these indications. MannKind and United Therapeutics entered into a worldwide exclusive licensing and collaboration agreement in September 2018 for the development and commercialization of Tyvaso DPI. In August 2021, the two companies established a commercial supply agreement that has an initial term through 2031. A next-generation formulation of treprostinil, Tyvaso DPI incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind's Afrezza Inhalation Powder, which was approved by the FDA in 2014. Tyvaso DPI is produced at MannKind's manufacturing facility in Connecticut.

05:41 EDT Autohome reports Q1 EPS 14c, consensus 40c - Reports Q1 revenue $232.09M, consensus $211.38M. Quan Long, chairman of the board of directors and CEO of Autohome, stated, "Since the beginning of this year, the resurgence of COVID-19 pandemic in multiple cities of China has impacted most industries including the automobile industry. Despite the challenging macro environment, Autohome reported a solid first quarter with revenues totaling RMB1.47 billion, which exceeded the market expectation, and maintained good profitability and high margin level. We believe our steady financial performance and strong cash flow could support Autohome to navigate through market uncertainties and focus on long-term development. Meanwhile, a healthy balance sheet and ample cash reserves allow us to continue to implement our share repurchase program and dividend policy. During this quarter, we significantly enhanced our content offerings with a greater variety of video and live streaming content and upgraded our new energy vehicle ("NEV") platform with a refreshed layout and user-friendly functionalities. These initiatives have successfully strengthened Autohome's content ecosystem while delivering a better user experience and have already gained substantial traction. In March 2022, our aggregated average daily active users grew by 7.5% year-over-year to 45.21 million, according to QuestMobile, further solidifying our leadership position in the auto media sector. In addition, revenues from NEV brands soared by 156.1% in the first quarter of 2022 compared to the same period last year. We are also encouraged by the sustained growth momentum in the number of our dealer customers who have adopt an increasingly variety of our data products. Supported by our strong network effect, innovation capabilities and visionary management team, we believe these advancements will further strengthen our eco-platform and empower us to capture new opportunities in the years to come."

05:27 EDT DocGo announces $40M share repurchase plan - DocGo announced that its board of directors has authorized a share repurchase program pursuant to which the company may purchase up to $40M of its common stock. Under the terms of the repurchase program, DocGo may purchase shares of its common stock on a discretionary basis from time to time through open market repurchases, privately negotiated transactions, or other means, including through Rule 10b5-1 trading plans.

05:07 EDT Yatsen reports Q1 EPS (1c), consensus (4c) - Reports Q1 revenue $140.5M, consensus $130.1M. "We remain focused on executing our strategy of building our brands, investing in R&D and pursuing sustainable growth in the first quarter of 2022," stated Jinfeng Huang, Founder, chairman and CEO of Yatsen. "We have already observed early progress, including the growing skincare business and narrowing net loss and non-GAAP net loss. Although the pandemic continues to negatively impact our business, including our offline stores and supply chain, we are working hard to transform Yatsen and optimize operations during these challenging times."